Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs (ALAB) Form 4 reports two consecutive insider sales by CEO & Director Jitendra Mohan on 17-18 Jul 2025 pursuant to a Rule 10b5-1 plan adopted 2 Dec 2024.
- 17 Jul 2025: 80,503 common shares sold through six estate-planning trusts at a weighted-average price of $94.37.
- 18 Jul 2025: 45,755 common shares sold through the same trusts at a weighted-average price of $100.25.
Total disposition: 126,258 shares (~1 % of reported holdings). Post-sale beneficial ownership remains substantial at roughly 9.8 million shares, including 2.26 million held directly and 7.54 million held indirectly across multiple trusts.
No derivative activity was disclosed. Because the sales were automatic and represent a small fraction of total ownership, they appear to be routine liquidity events; however, investors may monitor future filings for additional insider trends.
Astera Labs, Inc. (ALAB) – Form 4 insider transaction filed 07/11/2025
President, COO and Director Sanjay Gajendra reported the sale of 165,000 ALAB common shares on 07/09/2025 through three estate-planning trusts ("Trust 1", "Trust 2", "Trust 3") operating under a Rule 10b5-1 trading plan adopted on 11/30/2024.
- Shares sold & weighted-average prices
- Trust 1: 86,685 sh @ $98.5214 and 38,315 sh @ $99.2093
- Trust 2: 20,000 sh @ $98.2078
- Trust 3: 20,000 sh @ $98.2180
- Total shares sold: 165,000
- Approximate gross proceeds: ≈ $16.3 million (calculated from disclosed share counts and prices)
- Remaining holdings (indirect only):
- Trust 1: 5,805,545 shares
- Trust 2: 695,000 shares
- Trust 3: 695,000 shares
- Direct holding disclosed separately: 2,262,318 shares
The filing notes that Mr. Gajendra disclaims beneficial ownership except to the extent of any pecuniary interest and that the sales occurred automatically under the pre-set 10b5-1 plan, potentially mitigating concerns about timing or intent.
No derivative security transactions were reported. The sale reduces—but does not materially alter—the insider’s significant economic exposure, leaving a combined direct and indirect stake exceeding 9.4 million shares.
Astera Labs, Inc. (ALAB) has filed a Form 4 disclosing that Chief Executive Officer and Director Jitendra Mohan sold company stock on 9 and 10 July 2025 pursuant to a Rule 10b5-1 trading plan adopted 2 December 2024. In total, 18,264 common shares were sold through several estate-planning trusts at weighted-average prices of $100.0092 (6,982 shares on 7/09) and $102.4607 (11,282 shares on 7/10). Footnotes note price ranges of $100.00–$100.08 and $102.04–$103.14, respectively.
Following the transactions the trusts still hold a combined ≈7.6 million shares, while a separate direct holding of 2,262,318 shares is also reported, indicating that less than 1 % of Mohan’s beneficial ownership was divested. No derivative securities were involved, and the sales were executed automatically, limiting their informational content regarding future company prospects.
Astera Labs (ALAB) – Form 4 insider activity filed 07/07/2025
Director Manuel Alba disclosed the sale of 93,991 common shares on 02-03 July 2025. The disposals were executed through Casa Alameda 2007 LLC (13,991 sh) and the Alba Trust (80,000 sh) under a pre-arranged Rule 10b5-1 trading plan. Weighted-average sale prices ranged from $88.19 to $93.14 across 20 separate trades. No derivative securities were involved.
Following the transactions, Alba still beneficially owns about 2.31 million shares (1.89 m via Alba Trust, 418.9 k via Casa Alameda, 5 k via spouse, 2.4 k directly), indicating he retained roughly 96 % of his prior position.
The filing signals modest insider selling—around 4 % of his holdings—but the continuing sizeable stake and use of a 10b5-1 plan temper potential negative interpretation.
Astera Labs director Bethany Mayer executed multiple transactions on June 24-26, 2025, including both sales and transfers of common stock:
- Sold 686 shares on June 24 through a pre-planned Rule 10b5-1 trading plan at weighted average prices between $86.81-$88.50 per share
- Transferred 839 shares on June 26 to The Jantzen/Mayer Family 2002 Trust for no consideration
Following these transactions, Mayer directly owns 5,399 shares and indirectly owns 839 shares through the Trust. The sales were executed automatically under a Rule 10b5-1 plan established on November 25, 2024. As trustee of the Family Trust, Mayer disclaims beneficial ownership of the transferred shares except for any pecuniary interest.
Astera Labs CEO Jitendra Mohan executed planned sales of common stock on June 20, 2025, through a pre-established Rule 10b5-1 trading plan from December 2024. The transactions involved the sale of approximately 52,743 shares at weighted average prices ranging from $100.00 to $101.73 per share.
The sales were distributed across multiple trusts:
- Living Trust: 8,790 shares (remaining: 4,342,220 shares)
- Trust: 8,793 shares (remaining: 762,210 shares)
- 2021 Trust 1 & 2: 8,790 shares each (remaining: 762,217 shares each)
- 2022 Trust 1 & 2: 8,790 shares each (remaining: 512,218 shares each)
Mohan maintains direct ownership of 2,262,318 shares and serves as both Director and CEO. The filing includes standard disclaimers regarding beneficial ownership of trust-held securities.
Director Manuel Alba of Astera Labs (ALAB) reported multiple stock sales executed on June 20, 2025, through a pre-established Rule 10b5-1 trading plan from May 2024. The transactions involved:
- Casa Alameda 2007 LLC sold 3,709 shares at weighted average prices between $100.63-101.25 per share
- Alba Trust disposed of 16,441 shares at similar price ranges of $100.63-101.25 per share
Following these transactions, Alba maintains beneficial ownership of: 432,854 shares through Casa Alameda LLC, 1,967,757 shares via Alba Trust, 5,000 shares through spouse, and 2,351 shares directly. The filing includes disclaimers regarding beneficial ownership of trust and LLC holdings, limiting claims to Alba's pecuniary interests. All sales were executed according to the automated trading plan, demonstrating planned portfolio management rather than reactive selling.